Syndax Pharmaceuticals, Inc.
NASDAQ:SNDXBiotechnology
+$0.13 today
- Market cap
- $770.64M
- Beta
- 0.39
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$2.81
Volume 3.46M
Average 1.70M
SNDX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Syndax Pharmaceuticals, Inc.NASDAQ: SNDX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $7.92M rose 751.4% year over year, ahead of the -94.1% change in trailing-twelve-month financing cash flow. Sequentially, it rose 33.8% from the prior quarter. Over 3 fiscal years it compounded at -57.0% a year.
Context
- Financing cash flow amounted to 7.9% of revenue in FY2025, down 1484.3 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +751.4% holds above the trailing-twelve-month pace of -94.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 13.68M USD
- Year-over-year change
- -96.1%
- 4-year CAGR
- -41.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.68M | -96.1% |
| FY2024 | 2024-12-31 | 353.37M | +33.8% |
| FY2023 | 2023-12-31 | 264.13M | +53.3% |
| FY2022 | 2022-12-31 | 172.25M | +45.4% |
| FY2021 | 2021-12-31 | 118.46M | — |
Financing Cash Flow vs competitors
How SNDX compares with its peers on the latest reported figures
- SNDX's LTM Mar 2026 financing cash flow of $20.66M is the 9th largest of the 11 companies compared; the peer median is $220.17M.
- Its year-over-year change of -94.1% is the 9th highest of 11, against a peer median of +216.8%.
- Financing cash flow amounts to 9.5% of revenue for SNDX, versus a peer median of 105.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $444.83M | +5357.5% | — | 167.2% | |
| LTM Mar 2026 | $344.93M | +4594.2% | +454.4% | 970.5% | |
| LTM Jun 2026 | $313M | +30.4% | +145.5% | 267.5% | |
| LTM Mar 2026 | $306.39M | +17210.3% | +114.1% | — | |
| LTM Aug 2026 | $261.21M | +28.6% | +26.8% | 37.2% | |
| LTM Jun 2026 | $179.14M | -6.5% | +434.4% | 105.4% | |
| LTM Mar 2026 | $139.89M | +403.3% | -66.8% | — | |
| LTM Mar 2026 | $69.59M | +16083.5% | +247.3% | 44.3% | |
| LTM Mar 2026 | $20.66M | -94.1% | -57.0% | 9.5% | |
| LTM Dec 2025 | $10.49M | -95.8% | +236.9% | — | |
| LTM Jun 2026 | $8.3M | -95.9% | +13.0% | 7.9% | |
| Peer median (excluding SNDX) | $220.17M | +216.8% | +145.5% | 105.4% | |
Competitors are the stored peer set for SNDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 24.93M | (149.34M) | (209.36M) | (318.76M) | (285.42M) |
| Depreciation & Amortization | 43K | 33K | 12K | 8K | 6K |
| Deferred Income Tax | 255K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.32M | 16.02M | 30.95M | 43.03M | 47.5M |
| Change in Working Capital | (9.6M) | 1.66M | 31.86M | 13.27M | (79.32M) |
| Accounts Receivables | 0 | (3.47M) | 10.71M | (11.24M) | (36.83M) |
| Inventory | 0 | 3.47M | 0 | (366K) | (32.09M) |
| Accounts Payables | 2.16M | (1.32M) | 5.61M | 1.67M | 4.95M |
| Other Working Capital | (11.76M) | 2.98M | 15.54M | 23.21M | (15.35M) |
| Other Non-Cash Items | 187K | (2.05M) | (14.06M) | (12.45M) | (5.75M) |
| Operating Cash Flow | 29.13M | (133.68M) | (160.6M) | (274.9M) | (322.98M) |
| Capital Expenditures | (129K) | (225K) | 0 | 0 | (187K) |
| Acquisitions (Net) | 40.74K | 225K | 0 | 0 | 0 |
| Purchases of Investments | (294.72M) | (495.35M) | (354.61M) | (557.05M) | (195.81M) |
| Sales of Investments | 253.98M | 308.93M | 472.22M | 337.28M | 486.03M |
| Other Investing Activities | (40.74K) | 225K | 0 | 0 | 0 |
| Investing Cash Flow | (40.87M) | (186.19M) | 117.61M | (219.78M) | 290.04M |
| Debt Repayment | 0 | (21M) | 0 | 0 | 0 |
| Common Stock Issued | 86.34M | 181.39M | 258.09M | 9.72M | 13.68M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 32.13M | 11.86M | 6.04M | 343.65M | 0 |
| Financing Cash Flow | 118.46M | 172.25M | 264.13M | 353.37M | 13.68M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 106.72M | (147.61M) | 221.14M | (141.31M) | (19.27M) |
| Free Cash Flow | 29M | (133.9M) | (160.6M) | (274.9M) | (323.17M) |
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
Intrinsic Alpha fair value
Locked
Current Price
$8.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.